Moreover, the authors demonstrated the APL-like phenotype beneficially impacted RFS and OS, and its combination with coexisting TET2 or IDH1/2 mutations was more explicit to refine prognostic subgroups. This evidence concerns the gene TET2 and acute promyelocytic leukemia.